Arbutus Biopharma Corp (ABUS) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases, specifically developing imdusiran (AB-729) and AB-101 for the treatment of chronic hepatitis B (cHBV). The company is also actively litigating patent infringement claims against Moderna and Pfizer/BioNTech regarding its lipid nanoparticle (LNP) technology.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $0.53 million | $1.34 million | $13.03 million | $4.60 million |
| Net Loss | $(7.74) million | $(19.72) million | $(29.75) million | $(57.39) million |
| Operating Expenses | $9.19 million | $22.78 million | $45.90 million | $66.98 million |
| Cash & Equivalents | $22.41 million | $31.85 million | $22.41 million | $31.85 million |
| Total Liquidity (Cash + Investments) | $93.70 million | $122.62 million | $93.70 million | $122.62 million |
| Debt | $0 | $0 | $0 | $0 |
Note: Revenue includes non-cash royalty revenue from the sale of future royalties to OMERS. YTD 2025 revenue was significantly boosted by the recognition of deferred revenue following the termination of the Qilu partnership.
Material Changes vs. Prior Period
- Revenue Surge (YTD): Total revenue increased $8.4 million year-over-year for the nine months ended September 30, 2025. This was primarily driven by the recognition of $9.6 million in previously deferred revenue upon the mutual termination of the strategic partnership with Qilu Pharmaceutical in June 2025.
- Expense Reduction: Operating expenses decreased significantly ($21.1 million for the quarter; $21.1 million YTD) due to a major restructuring in Q1 2025. This included a 57% workforce reduction, the exit of the Warminster, PA headquarters, and the discontinuation of in-house scientific research.
- Restructuring Costs: The company recorded $12.6 million in restructuring costs for the nine months ended September 30, 2025, compared to $3.6 million in the prior year period. This included severance, lease impairments, and equity award modifications.
- Cash Burn: Net cash used in operating activities decreased to $35.0 million for the nine months ended September 30, 2025, from $54.5 million in the prior year period, reflecting successful cost-cutting measures.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes the company has sufficient cash resources ($93.7 million) to fund operations for at least the next 12 months. The company expects to significantly reduce net cash burn in 2025 compared to 2024.
- Strategic Shift: The company has ceased discovery efforts and halted preparations for the IM-PROVE III trial to focus resources on advancing imdusiran and AB-101. It has regained global rights to imdusiran following the Qilu termination.
- Legal Proceedings:
- Moderna: U.S. trial set for March 2026. Five international lawsuits filed in March 2025 (including Unified Patent Court hearings in May 2026).
- Pfizer/BioNTech: A favorable claim construction ruling was issued in September 2025.
- Risks: The company remains dependent on external funding for future development. Outcomes of patent litigation are uncertain. Clinical trial results for imdusiran and AB-101 are not guaranteed.
Investor Verification Checklist
- Runway Validation: Verify the $93.7 million liquidity position against the projected cash burn rate to confirm the 12-month operational runway.
- Qilu Termination Impact: Confirm that the $9.6 million revenue recognition was a one-time non-cash event and assess the long-term impact of losing the Greater China commercialization partner.
- Restructuring Completion: Monitor the execution of the 57% workforce reduction and the exit of the corporate headquarters to ensure projected cost savings materialize.
- Litigation Timeline: Track the March 2026 trial date for the Moderna lawsuit and the May 2026 hearings in the Unified Patent Court as potential catalysts.
- Clinical Data: Review upcoming data presentations for imdusiran (IM-PROVE I & II) and AB-101 to assess the probability of achieving a functional cure for cHBV.